|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Fu,Chun-Chao | Wang,Cheng-Lung | Joanne Chang | 02-23252295 | 10F., No.1, Songzhi Rd., Xinyi Dist., Taipei City 110411, Taiwan (R.O.C.)Taiwan Taipei 110411 | 2011/12/28 | |||
Agent for litigious and non-litigious matters |
Tel of Agent for litigious and non-litigious matters |
Address of Agent for litigious and non-litigious matters |
||||||
Wang,Cheng-Lung | 02-23252295 | 台北市信義區松智路1號10樓 | ||||||
Industry | Main Business | |||||||
Other | The Corporation officially changed the name to Raku Co., Ltd. upon approval of the shareholders' meeting in 2021, and major investments were transformed from original healthcare product sales to manufacturing and sales of luxury accessories. The former Kino Biotech Co., Ltd. was a holding company incorporated in the Cayman Islands on August 9, 2010 and was a TEPx listed company in 2011. The Corporation officially established its Taiwan headquarters and started the transformation in 2018. The major businesses comprise manufacturing and sales of luxury accessories, and major products are metal buttons applied to luxury leather products since 2021. The operation and research center of the Group is based in Taiwan. Our main goal is to increase turnover and grow profits for shareholders. |
Market Information ( 2024/04/26 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
19.247 | 13.30 | 13.05 | 13.25 | -0.15 | 9 | .00 | N/A | N/A | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/26) |
TPEx measures adopted (2024/04/26) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |